Coverage
-
June 16, 2017
A California federal court on Thursday ordered a former InterMune Inc. director and his friend to collectively pay about $745,600 in disgorgement and interest over their insider trading scheme that capitalized on nonpublic information about the pending approval of InterMune's lung disease drug.
10 other articles on this case.
View all »